338 related articles for article (PubMed ID: 23446198)
1. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
[TBL] [Abstract][Full Text] [Related]
2. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
[TBL] [Abstract][Full Text] [Related]
3. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
[TBL] [Abstract][Full Text] [Related]
4. Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis.
Uhlmann C; Kaehler J; Harris MS; Unser J; Arolt V; Lencer R
J Psychiatr Pract; 2014 Sep; 20(5):405-10. PubMed ID: 25226204
[TBL] [Abstract][Full Text] [Related]
5. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
7. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
[TBL] [Abstract][Full Text] [Related]
8. Optimizing early prediction for antipsychotic response in schizophrenia.
Chang YC; Lane HY; Yang KH; Huang CL
J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
[TBL] [Abstract][Full Text] [Related]
9. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.
Samara MT; Leucht C; Leeflang MM; Anghelescu IG; Chung YC; Crespo-Facorro B; Elkis H; Hatta K; Giegling I; Kane JM; Kayo M; Lambert M; Lin CH; Möller HJ; Pelayo-Terán JM; Riedel M; Rujescu D; Schimmelmann BG; Serretti A; Correll CU; Leucht S
Am J Psychiatry; 2015 Jul; 172(7):617-29. PubMed ID: 26046338
[TBL] [Abstract][Full Text] [Related]
10. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
[TBL] [Abstract][Full Text] [Related]
13. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
[TBL] [Abstract][Full Text] [Related]
14. [Relationships between insight and medication adherence in subjects with psychosis].
Droulout T; Liraud F; Verdoux H
Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
[TBL] [Abstract][Full Text] [Related]
15. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia.
Sapra M; Vahia IV; Reyes PN; Ramirez P; Cohen CI
Schizophr Res; 2008 Dec; 106(2-3):348-55. PubMed ID: 18851906
[TBL] [Abstract][Full Text] [Related]
16. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
17. Early prediction of antipsychotic response in schizophrenia.
Correll CU; Malhotra AK; Kaushik S; McMeniman M; Kane JM
Am J Psychiatry; 2003 Nov; 160(11):2063-5. PubMed ID: 14594760
[TBL] [Abstract][Full Text] [Related]
18. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods.
Chen L; Ascher-Svanum H; Stauffer V; Kinon BJ; Kollack-Walker S; Ruberg S
Schizophr Res; 2009 Aug; 113(1):34-40. PubMed ID: 19564097
[TBL] [Abstract][Full Text] [Related]
19. Early prediction of antipsychotic nonresponse among patients with schizophrenia.
Leucht S; Busch R; Kissling W; Kane JM
J Clin Psychiatry; 2007 Mar; 68(3):352-60. PubMed ID: 17388703
[TBL] [Abstract][Full Text] [Related]
20. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
